News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
645,937 Results
Type
Article (44825)
Company Profile (169)
Press Release (600943)
Multimedia
Podcasts (63)
Webinars (11)
Section
Business (179474)
Career Advice (2861)
Deals (33168)
Drug Delivery (115)
Drug Development (74227)
Employer Resources (190)
FDA (15785)
Job Trends (15003)
News (309734)
Policy (29853)
Tag
2024 BioForest Digital (2)
2024 BioForest Standard (1)
2024 BioMidwest Digital (4)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (7)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (3)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2813)
Academic (2)
Accelerated approval (5)
Adcomms (27)
Allergies (87)
Alliances (45226)
ALS (95)
Alzheimer's disease (1443)
Antibody-drug conjugate (ADC) (116)
Approvals (15785)
Artificial intelligence (269)
Autoimmune disease (25)
Automation (15)
Bankruptcy (299)
Best Places to Work (12203)
BIOSECURE Act (19)
Biosimilars (100)
Biotechnology (113)
Bladder cancer (65)
Brain cancer (25)
Breast cancer (269)
Cancer (2104)
Cardiovascular disease (168)
Career advice (2387)
Career pathing (33)
CAR-T (153)
Cell therapy (428)
Cervical cancer (20)
Clinical research (60120)
Collaboration (825)
Compensation (518)
Complete response letters (22)
COVID-19 (2578)
CRISPR (40)
C-suite (236)
Cystic fibrosis (105)
Data (2086)
Decentralized trials (1)
Denatured (25)
Depression (43)
Diabetes (255)
Diagnostics (6656)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (46)
Drug discovery (119)
Drug pricing (98)
Drug shortages (22)
Duchenne muscular dystrophy (91)
Earnings (69596)
Editorial (39)
Employer branding (25)
Employer resources (163)
Events (105843)
Executive appointments (727)
FDA (16984)
Featured Employer (62)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (741)
Gene editing (107)
Generative AI (24)
Gene therapy (300)
GLP-1 (697)
Government (4255)
Grass and pollen (4)
Guidances (47)
Healthcare (20053)
Huntington's disease (24)
IgA nephropathy (26)
Immunology and inflammation (111)
Indications (27)
Infectious disease (2722)
Inflammatory bowel disease (144)
Inflation Reduction Act (11)
Influenza (51)
Intellectual property (95)
Interviews (551)
IPO (16362)
IRA (35)
Job creations (3234)
Job search strategy (1993)
Kidney cancer (10)
Labor market (35)
Layoffs (453)
Leadership (21)
Legal (6609)
Liver cancer (68)
Lung cancer (302)
Lymphoma (132)
Machine learning (5)
Management (65)
Manufacturing (287)
MASH (63)
Medical device (14061)
Medtech (14066)
Mergers & acquisitions (17405)
Metabolic disorders (640)
Multiple sclerosis (76)
NASH (19)
Neurodegenerative disease (94)
Neuropsychiatric disorders (21)
Neuroscience (1976)
NextGen: Class of 2025 (6947)
Non-profit (4879)
Northern California (2587)
Now hiring (38)
Obesity (334)
Opinion (236)
Ovarian cancer (76)
Pain (89)
Pancreatic cancer (77)
Parkinson's disease (156)
Partnered (20)
Patents (226)
Patient recruitment (101)
Peanut (50)
People (53893)
Pharmaceutical (44)
Pharmacy benefit managers (18)
Phase I (18732)
Phase II (26601)
Phase III (19982)
Pipeline (1115)
Policy (124)
Postmarket research (2143)
Preclinical (7891)
Press Release (69)
Prostate cancer (97)
Psychedelics (32)
Radiopharmaceuticals (256)
Rare diseases (385)
Real estate (5407)
Recruiting (74)
Regulatory (20978)
Reports (51)
Research institute (2536)
Resumes & cover letters (461)
Rett syndrome (4)
RNA editing (3)
RSV (46)
Schizophrenia (71)
Series A (126)
Series B (82)
Service/supplier (10)
Sickle cell disease (58)
Southern California (2235)
Special edition (14)
Spinal muscular atrophy (152)
Sponsored (27)
Startups (3367)
State (2)
Stomach cancer (10)
Supply chain (66)
Tariffs (22)
The Weekly (37)
United States (22670)
Vaccines (648)
Venture capitalists (38)
Weight loss (216)
Women's health (30)
Worklife (19)
Date
Today (31)
Last 7 days (506)
Last 30 days (2457)
Last 365 days (33956)
2025 (9568)
2024 (36554)
2023 (41879)
2022 (52615)
2021 (57515)
2020 (56045)
2019 (49345)
2018 (37176)
2017 (32871)
2016 (31455)
2015 (36714)
2014 (26161)
2013 (20854)
2012 (22629)
2011 (23507)
2010 (21055)
Location
Africa (836)
Alabama (58)
Alaska (7)
Arizona (180)
Arkansas (12)
Asia (37920)
Australia (6746)
California (5882)
Canada (1956)
China (497)
Colorado (261)
Connecticut (276)
Delaware (138)
Europe (87320)
Florida (877)
Georgia (214)
Hawaii (1)
Idaho (59)
Illinois (549)
India (26)
Indiana (312)
Iowa (8)
Japan (147)
Kansas (102)
Kentucky (26)
Louisiana (10)
Maine (70)
Maryland (870)
Massachusetts (4519)
Michigan (237)
Minnesota (398)
Mississippi (2)
Missouri (86)
Montana (31)
Nebraska (25)
Nevada (62)
New Hampshire (69)
New Jersey (1704)
New Mexico (30)
New York (1686)
North Carolina (1010)
North Dakota (8)
Northern California (2587)
Ohio (201)
Oklahoma (14)
Oregon (34)
Pennsylvania (1325)
Puerto Rico (11)
Rhode Island (31)
South America (1164)
South Carolina (20)
South Dakota (1)
Southern California (2235)
Tennessee (101)
Texas (874)
Utah (182)
Virginia (141)
Washington D.C. (62)
Washington State (549)
West Virginia (3)
Wisconsin (57)
645,937 Results for "ab science".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell disease
April 14, 2025
·
7 min read
Press Releases
AB Science will participate in the Biomed Forum investors conference
January 22, 2025
·
2 min read
Press Releases
AB Science today provides an update on its masitinib platform
January 30, 2025
·
4 min read
Press Releases
AB Science: Revenues for the first half of 2024 and update on AB Science’s activities
October 10, 2024
·
21 min read
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
AB Science SA is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
March 7, 2024
·
11 min read
Press Releases
AB Science provides a summary of the webcast held on December 16, 2024
December 17, 2024
·
7 min read
Press Releases
Notice to Annual General Meeting in AlzeCure Pharma AB
April 9, 2025
·
9 min read
Business
AB Science reports its revenues for the year 2023 and provides an update on its activities
AB Science SA reports its revenues for the year 2023 and provides an update on its activities.
May 15, 2024
·
23 min read
Press Releases
BioInvent International AB Publishes Annual Report 2024
April 4, 2025
·
1 min read
AB Science provides an update on the application for conditional marketing authorisation of masitinib in ALS
AB Science SA (Euronext - FR0010557264 - AB) today announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a trending toward a negative opinion on the application for conditional marketing authorisation of masitinib in the treatment of amyotrophic lateral sclerosis (ALS), following an oral explanation held at the 28 May meeting of the CHMP.
May 29, 2024
·
3 min read
1 of 64,594
Next
